| Chronic graft-versus-host disease
Jakafi vs Rezurock
Side-by-side clinical, coverage, and cost comparison for chronic graft-versus-host disease.Deep comparison between: Jakafi vs Rezurock with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRezurock has a higher rate of injection site reactions vs Jakafi based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Rezurock but not Jakafi, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Jakafi
Rezurock
At A Glance
Oral
Twice daily
JAK1/JAK2 inhibitor
Oral
Daily
ROCK2 inhibitor
Indications
- Myelofibrosis
- Polycythemia Vera
- Acute GVH disease
- Chronic graft-versus-host disease
- Chronic graft-versus-host disease
Dosing
Myelofibrosis Starting dose based on platelet count: 20 mg orally twice daily (>200 x 10^9/L), 15 mg twice daily (100-200 x 10^9/L), or 5 mg twice daily (50 to <100 x 10^9/L); doses may be titrated up to 25 mg twice daily based on safety and efficacy.
Polycythemia Vera 10 mg orally twice daily starting dose; doses may be titrated up to 25 mg twice daily based on safety and efficacy.
Acute GVH disease 5 mg orally twice daily starting dose; may increase to 10 mg twice daily after at least 3 days if ANC and platelet counts are not decreased by 50% or more relative to the first day of dosing.
Chronic graft-versus-host disease 10 mg orally twice daily starting dose; taper after 6 months in patients with response who have discontinued therapeutic doses of corticosteroids.
Chronic graft-versus-host disease 200 mg orally once daily with food until progression of chronic GVHD requiring new systemic therapy; increase to 200 mg twice daily when coadministered with strong CYP3A inducers or proton pump inhibitors.
Contraindications
—
—
Adverse Reactions
Most common Thrombocytopenia, anemia, neutropenia, bruising, dizziness, headache, infections, edema, hemorrhage, fatigue
Serious Thrombocytopenia, anemia, neutropenia, infections, non-melanoma skin cancer, major adverse cardiovascular events, thrombosis, secondary malignancies
Postmarketing Herpes simplex virus reactivation and/or dissemination
Most common (>=20%) Infections, asthenia, nausea, diarrhea, dyspnea, cough, edema, hemorrhage, abdominal pain, musculoskeletal pain, headache, phosphate decreased, gamma glutamyl transferase increased, lymphocytes decreased, hypertension
Pharmacology
Ruxolitinib is a kinase inhibitor that selectively inhibits JAK1 and JAK2, which mediate cytokine and growth factor signaling important for hematopoiesis and immune function; dysregulated JAK1/JAK2 signaling underlies myelofibrosis, polycythemia vera, and GVHD pathogenesis.
Belumosudil is a ROCK inhibitor that selectively inhibits ROCK2 (IC50 approximately 100 nM) and ROCK1 (IC50 approximately 3 uM), down-regulating proinflammatory STAT3/STAT5 signaling and Th17/Treg imbalance while inhibiting pro-fibrotic signaling implicated in chronic GVHD.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Jakafi
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (10/12) · Qty limit (11/12)
Rezurock
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (11/12) · Qty limit (9/12)
UnitedHealthcare
Jakafi
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (8/8) · Qty limit (7/8)
Rezurock
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (4/8) · Qty limit (1/8)
Humana
Jakafi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Rezurock
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Jakafi.
$10/momo
Kadmon ASSIST Copay Savings Card: RezurockCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
JakafiView full Jakafi profile
RezurockView full Rezurock profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.